PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated
Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026
Read more at globenewswire.comClimb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Provided By GlobeNewswire – Last update: